TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05140538

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SRP + toothpaste + mouthwash
Description: Use of domiciliary products twice a day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SRP + toothpaste
Description: Use of domiciliary products twice a day
Study: NCT05428787

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left Bundle Branch Area Pacing
Description: The patients will be allocated by randomization to receive the intervention of Left Bundle Branch Area Pacing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CRT
Description: The patients will be allocated by randomization to receive the intervention of CRT.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AV node ablation
Description: AV node ablation after 4 weeks of CRT implant or LBBAP implant.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AV node ablation
Description: AV node ablation after 4 weeks of CRT implant or LBBAP implant.
Study: NCT04457882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intraperitoneal Laparoscopic Radical Prostatectomy Without Drainage Tube
Description: No place the drainage tube after the intraperitoneal Laparoscopic Radical Prostatectomy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intraperitoneal Laparoscopic Radical Prostatectomy With Drainage Tube
Description: Place the drainage tube after the intraperitoneal Laparoscopic Radical Prostatectomy
Study: NCT04200846

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: Subjects in this group will be asked to exercise 5 days a week. Two days on-site with an Exercise Physiologist and the other 3 days at home.
Study: NCT06390748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esmolol
Description: The primary intervention is the administration of Esmolol. Esmolol was specifically used to evaluate its immunomodulatory effects in patients with sepsis in the study. The dosage was tailored to achieve optimal heart rate control, an integral part of the therapeutic strategy aiming to mitigate the hyperadrenergic state often seen in sepsis. Alongside Esmolol, daily electrocardiogram (ECG) monitoring was incorporated to observe any changes in the QT interval, ensuring cardiac safety due to the known potential cardiac effects of beta-blockers.
Study: NCT05079308

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral sealing device for surgical mask or filtering face piece
Description: The individuals used a Peripheral Sealing Device on a surgical mask or a filtering face piece mask and were submitted to a qualitative fit test, regulated by the Occupational Security and Health Administration (USA).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral sealing device for surgical mask or filtering face piece
Description: The individuals used a Peripheral Sealing Device on a surgical mask or a filtering face piece mask and were submitted to a qualitative fit test, regulated by the Occupational Security and Health Administration (USA).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral sealing device for surgical mask or filtering face piece
Description: The individuals used a Peripheral Sealing Device on a surgical mask or a filtering face piece mask and were submitted to a qualitative fit test, regulated by the Occupational Security and Health Administration (USA).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral sealing device for surgical mask or filtering face piece
Description: The individuals used a Peripheral Sealing Device on a surgical mask or a filtering face piece mask and were submitted to a qualitative fit test, regulated by the Occupational Security and Health Administration (USA).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IIR Surgical mask with Filtering face piece
Description: The individuals used a IIR surgical mask with a filtering face piece mask and were submitted to a qualitative fit test, regulated by the Occupational Security and Health Administration (USA).
Study: NCT06514066

Intervention type: DRUG
Group type: OTHER
Intervention: Cannabidiol Oil
Description: The study intervention involves the administration of high purity Cannabidiol (CBD) in vegan soft gel capsule form. Dosing will range between 200 mg and 400 mg and will be administered twice daily. The CBD capsule is water-soluble to improve its bioavailability and absorption in the body.

Intervention type: DRUG
Group type: OTHER
Intervention: Cannabidiol Oil
Description: The study intervention involves the administration of high purity Cannabidiol (CBD) in vegan soft gel capsule form. Dosing will range between 200 mg and 400 mg and will be administered twice daily. The CBD capsule is water-soluble to improve its bioavailability and absorption in the body.
Study: NCT06170047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chicago Parent Program for Foster Care
Description: CPP-FC consists of 12 two-hour sessions delivered virtually by two trained group leaders over 16 weeks (11 concurrent weeks, 1 one-month booster) in a group-based format. Foster and kinship caregivers of young children are systematically taught parenting skills through group discussions, videotaped vignettes, structured role play and weekly homework assignments.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The Usual Care control will receive services from the county, CHECK clinic, and for licensed caregivers, their licensing agency per usual care. Caregivers receive training and support from their county and/or private licensing agency, children are referred to community services by the caseworker when behaviors emerge, and support from behavioral health specialists is available when caregivers request them.
Study: NCT05505084

Intervention type: PROCEDURE
Intervention: Tooth extraction and ridge preservation using different barrier mermbranes
Description: The hopeless and unrestorable teeth are planned for extraction and implant placement.

Intervention type: PROCEDURE
Intervention: Tooth extraction and ridge preservation using different barrier mermbranes
Description: The hopeless and unrestorable teeth are planned for extraction and implant placement.

Intervention type: PROCEDURE
Intervention: Tooth extraction and ridge preservation using different barrier mermbranes
Description: The hopeless and unrestorable teeth are planned for extraction and implant placement.

Intervention type: PROCEDURE
Intervention: Tooth extraction and ridge preservation using different barrier mermbranes
Description: The hopeless and unrestorable teeth are planned for extraction and implant placement.

Intervention type: PROCEDURE
Intervention: Tooth extraction and ridge preservation using different barrier mermbranes
Description: The hopeless and unrestorable teeth are planned for extraction and implant placement.
Study: NCT05408078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SLEEPexpert
Description: SLEEPexpert 1.0 is the first version of an online Program to treat Insomnia. The internet-based self-help platform used for the implementation of CBT-I in this study has been developed by the University of Bern (Prof. Dr. Thomas Berger), has been used successfully in previous trials and has received a CE mark in 2018.~The device is intended for patients with mental disorders and insomnia who are treated for mental disorders in a hospital or an outpatient unit. No specific training is needed to operate the application.~There is no available clinical research data to date on exactly this product. However, the therapeutic content that is used in this study is based on Cognitive Behavioral Therapy for insomnia (CBT-I). This intervention has been found to be highly effective and without lasting adverse effects in many studies and is recommended for the treatment of insomnia in current clinical guidelines.

Intervention type: OTHER
Group type: OTHER
Intervention: TAU plus sleep monitoring
Description: Treatment aus Usual and a Sleep Monitoring App will be used. This is already described in the Arm Section
Study: NCT04612504

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SynOV1.1
Description: SynOV1.1 will be administered intratumorally.
Study: NCT06128759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focusing on Maryam's Flower
Description: Effect of Focusing on Maryam's Flower During the First Phase of the labor
Study: NCT05326984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be administered orally to the experimental group by randomization at a dose of 1000mgm2 per day, with maximum dose of 850mg three times a day, from day -7 to the end of the remission induction period.
Study: NCT05209503

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AccuFFRangio-guided strategy
Description: In this study, the AccuFFRangio-guided strategy will be applied to in the AccuFFRangio group in which calculation of the AccuFFRangio values of all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and with suitability to PCI revascularization will be carried out. If AccuFFRangio ≤ 0.80, then simultaneous PCI revascularization of target blood vessels will be carried out. If AccuFFRangio \> 0.80, then no PCI revascularization of target blood vessels will be carried out.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Angiography-guided strategy
Description: In this study, CAG-guided strategy will be used for the control group, i.e., in accordance with current guideline recommendations, all target coronary arteries with lesions with diameter stenosis of ≥ 70% (visual estimation) and suited for PCI revascularization will undergo PCI revascularization.
Study: NCT05775471

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and urine collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MR Urography
Description: Undergo MRU

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nephroureterectomy
Description: Undergo nephroureterectomy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT05711004

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education via SMS
Description: Participants in the experimental group will receive three messages per week in the morning (9-10 am) for three months. The investigators will call them every month to ensure that the SMS is delivered.
Study: NCT04751890

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured home-based exercise
Description: Low-intensity interval walking program prescribed at hospital and performed at daily at home

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking advice
Description: Walking advice according to the guidelines for peripheral artery disease patients
Study: NCT06416904

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: archwire stopper mesial to the maxillary first molar group
Description: canine retraction after the extraction of the maxillary first premolars with archwire stoppers is mesial to the maxillary first molars.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: inter-radicular mini-screw
Description: canine retraction after the extraction of the maxillary first premolars, with the maxillary first molars indirectly anchored to the inter-radicular mini-screw.
Study: NCT04966546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Hydrochloride
Description: Active drug arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Simple syrup with peppermint oil added to match the commercial solution and make it indistinguishable
Study: NCT06022952

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stone MD stent radar
Description: Mobile app

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stone MD stent radar
Description: Mobile app
Study: NCT04687579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening
Description: Screening: All health professionals at the hospitals will participate in the screening of umbilical hernia. The screening will be done in the outpatient clinic, the Emergency Department and at the hospital wards.

Intervention type: OTHER
Group type: OTHER
Intervention: Screening
Description: Screening: All health professionals at the hospitals will participate in the screening of umbilical hernia. The screening will be done in the outpatient clinic, the Emergency Department and at the hospital wards.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative optimization
Description: Ascites will be drained using percutaneous drainage or PleurX. Diuretics be used to control ascites preoperative. Haemoglobin \< 5 mmol/L indicates the need for red blood cell concentrates using two dosage SAG-M (350-400 mL of red blood cell concentrates in each dose) will be done. Thrombocytopenia \< 150 10\^9/L will be treated with a TPO-analog using avatrombopag 40-60 mg dispensed as an intravenous fluid. Culture verified infection will be treated with specific antibiotics depending on the blood culture. International Normalized Ratio \> 1.7 will be treated with either phytomenadion, Octaplex or fresh frozen plasma depending on the INR.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical hernia repair
Description: A curved incision placed superiorly or inferiorly around the umbilicus. The umbilicus proper is retained in the skin flap. The blunt dissection is made to the hernia sac. The neck of the herniated sac is then dissected from adjacent tissues by a combination of blunt and sharp dissection. The edges of the fascial defect are measured and the fascial defect is closed with a non-absorbable running suture 2-0. A fitted lightweight polypropylene mesh is placed in an onlay fashion and fixed with 4-8 single non-absorbable sutures in the corners and at the midline, with a mesh overlap of at least 4 cm. The umbilicus is re-inserted with a single knot absorbable suture 3-0. Hemostasis is ensured. Skin closure is performed with Nylon suture 3-0. 20 ml bupivacaine 0.5% is injected to the fascia for early pain control.
Study: NCT05956951

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop auditory stimulation
Description: Closed-loop auditory stimulation will be administered by a wearable EEG device (Philips SmartSleep Deep Sleep Headband). The EEG device will deliver auditory stimulation when slow-wave (deep) sleep is detected. Auditory stimulation will consist of 50ms long tones separated from each other by a fixed one-second inter-tone interval. The volume of each tone will be linearly modulated by sleep-depth such that louder (or softer) tones were played during deeper (or shallower) sleep.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop auditory stimulation
Description: Closed-loop auditory stimulation will be administered by a wearable EEG device (Philips SmartSleep Deep Sleep Headband). The EEG device will deliver auditory stimulation when slow-wave (deep) sleep is detected. Auditory stimulation will consist of 50ms long tones separated from each other by a fixed one-second inter-tone interval. The volume of each tone will be linearly modulated by sleep-depth such that louder (or softer) tones were played during deeper (or shallower) sleep.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham auditory stimulation
Description: Sham auditory stimulation consists of closed-loop auditory stimulation not being administered. A wearable EEG device (Philips SmartSleep Deep Sleep Headband) will not deliver closed-loop auditory stimulation and tones will not be played.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham auditory stimulation
Description: Sham auditory stimulation consists of closed-loop auditory stimulation not being administered. A wearable EEG device (Philips SmartSleep Deep Sleep Headband) will not deliver closed-loop auditory stimulation and tones will not be played.
Study: NCT05107856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRT1419
Description: PRT1419 will be administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRT1419
Description: PRT1419 will be administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRT1419
Description: PRT1419 will be administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine will be administered by intravenous or subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered orally
Study: NCT05435456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Strengthening and Relaxation Exercises
Study: NCT05266378

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PECs block
Description: The PECs block is performed immediately after induction of anesthesia, and 0.375% concentration of ropivacaine (carbiropivacaine injection, Fresinius Kavi Korea Co., Ltd.) is used with a 25 G 5 cm (or 8 cm) needle to induce ultrasound-guided pectoralis major (pectoralis major). 10mL (PECs I block) into the fascia between the pectoralis minor muscle) and the pectoralis minor muscle, and 20mL (PECs II block) between the pectoralis minor and serratus anterior muscle.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Not receiving PECs Block
Description: In this group, the PECs block was not implemented.
Study: NCT05915572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Mobilization Technique
Description: The therapist applied passive accessory glide to increase shoulder flexion, abduction, external rotation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Physical Therapy Program
Description: Myofascial release and ROM ex. 3 sessions per week for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Physical Therapy Program
Description: Myofascial release and ROM ex. 3 sessions per week for 6 weeks.
Study: NCT06150235

Intervention type: OTHER
Intervention: Data collection
Description: Data collection
Study: NCT03742414

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Tri-lipid skin barrier cream (Epiceram)
Description: The aim is to compare the effect of proactive sequential skin care, including the twice daily use of a tri-lipid skin barrier cream (Epiceram) and proactive use of fluticasone proprionate cream, against reactive AD therapy, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate Cream 0.05%
Description: Proactive use of fluticasone proprionate cream for inflammation of the skin, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants' eczema will be managed by their primary physician, i.e. standard of care with routine reactive topical products for atopic dermatitis flares.
Study: NCT05046405

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial Direct Current Stimulation (tDCS) has been suggested to the peripartum period combining antidepressant eﬀects with low risks. In tDCS a low intensity constant current is delivered to the scalp with sub-threshold eﬀect on neurons' resting membrane potential. Long stimulation sessions lead to lasting eﬀects and neuroplastic changes. Local tDCS eﬀects target calcium-dependent synaptic plasticity and distal eﬀects alter the networks' connectivity, synchronicity and oscillatory patterns. tDCS applications aim to counteract the hypoactivity of the frontoparietal network and the left sided hyperactivity of the default mode network associated with depressive symptoms.
Study: NCT05530265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the smart watch and Samsung Health app
Description: Use the smart watch (Galaxy Watch 4, Samsung Electronics Co., Ltd., Korea) and the Samsung Health app (Samsung Electronics Co., Ltd., Korea) for 90 days of positive airway pressure treatment
Study: NCT06238167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab, 200mg Q3W, max 16 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 therapy
Description: S1 d1-14 bid (\< 1.25m\^2 40mg, 1.25m\^2-1.5m\^2 50mg, ≥ 1.5m\^2 60mg), followed by 7 days off (Q3W, max 16 cycles).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose SOX therapy
Description: Oxaliplatin: 78mg/m\^2, d1, S-1: 50mg d1-14 bid, followed by 7 days off (Q3W, max 8 cycles).
Study: NCT01112540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 0.1 mg/kg Intravenous bolus

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: 0.1 mg/kg Intravenous bolus
Study: NCT06276361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral risperidone; QUAR F1/2, Dose 1 - Gluteal
Description: Dose level 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral risperidone; QUAR F1/2, Dose 2 - Gluteal
Description: Dose level 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral risperidone; QUAR F1/2, Dose 3 - Gluteal
Description: Dose level 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral risperidone; QUAR F1/2, Dose 3 - Deltoids
Description: Dose level 3
Study: NCT05595824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir (Esperavir)
Description: Capsules 800 mg, 2 times a day with 12 ±2 hours interval for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: The administration of 'Standard of care' drugs was done according to the regimen recommended in the 'COVID-19 TreatmentGuidelines'(Version 14 of 27.12.2021), or inforce at the time of the study
Study: NCT04905121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Psilocybin will be provided in form of dry filled capsules and administered orally in three ascending doses